Answers are grounded in this paper and cite their sources.
This Viewpoint discusses the optimal treatment duration of glucagon-like peptide-1 receptor agonists in people with obesity and the benefits of off-ramping, the tapering of these antiobesity medications following an initial treatment period.
No takes yet. Share an insight, caveat, or question.
Manne‐Goehler et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: